English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 65231/98744 (66%)
造訪人次 : 31975071      線上人數 : 2513
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://tkuir.lib.tku.edu.tw/dspace/handle/987654321/120002


    題名: Renal protective efect of sacubitril/valsartan in patients with heart failure
    作者: Hsieh, Hui Ling;Chen, Chun You;Chen, Cheng Hsien;Hsu, Shih Chang;Huang, Wen Cheng;Sue, Yuh Mou;Lin, Feng Yen;Shih, Chun Ming;Chang, Yue Cune;Huang, Po Hsun;Liu, Chung Te
    日期: 2021-02-25
    上傳時間: 2021-03-04 12:12:05 (UTC+8)
    摘要: Sacubitril/valsartan is a combined neprilysin inhibitor/angiotensin II receptor blocker designed for
    treatment of heart failure (HF). Nonetheless, its renal protective effect remained an issue of debate.
    This retrospective cohort study investigated the renal protective effect of sacubitril/valsartan in HF
    patients. HF patients on sacubitril/valsartan or valsartan for > 30 days were matched for gender, age,
    estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction (LVEF) to be enrolled
    into analysis. The follow-up period was 18 months. The outcomes included end eGFR, renal function
    decline defined as 20% reduction of eGFR, mortality, and HF-related hospitalization. Each group had
    137 patients after matching. The mean age was 72.7 years and 65.7% were male. Mean eGFR was
    70.9 mL/min/1.73 m2 and LVEF was 54.0% at baseline. Overall, the eGFR of sacubitril/valsartan groups
    was significantly higher than valsartan group at the end (P < 0.01). Subgroup analysis showed that
    the difference in eGFR was significant in subgroups with LVEF ≥ 40% or eGFR ≥ 60 mL/min/1.73 m2.
    Multivariate Cox regression model showed that sacubitril/valsartan group had significantly reduced
    risk for renal function decline (hazard ratio: 0.5, 95% confidence interval: 0.3–0.9). Kaplan–Meier
    curve showed no difference in the risk for cardiovascular mortality, all-cause mortality or HF-related
    hospitalization. We showed renal protective effect of neprilysin inhibition in HF patients and specified
    that subgroups with LVEF ≥ 40% or eGFR ≥ 60 mL/min/1.73 m2 were sensitive to this effect, suggesting
    an optimal subgroup of this treatment.
    關聯: Scientific Reports 11(1), 4593
    DOI: 10.1038/s41598-021-84118-8
    顯示於類別:[應用數學與數據科學學系] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML296檢視/開啟

    在機構典藏中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋